Investor readiness for health companies raising $5M or more.
A CFO who has sat on both sides of the table reviews your business model, financial model, and pitch deck, gets your finances in order, and connects you to investors in her network.
Built for scientist-led teams that need to show investors where the money is made, not just the science.
A CFO's eye before investors get theirs.
Malgorzata Guyot has been the external Big 4 auditor, the head of internal audit, the CFO of a private equity-owned pharmaceutical company, and an investor. Over 20 years in finance and audit across pharma, manufacturing, and Big 4, in Europe and North America. She knows what a due diligence team opens first, because she has been the person opening it.
She is a member of the Charlotte Angel Fund, mentors founders at The Pearl, and shows up at Connect Labs. She is already in the room.
How it works
Three steps, in order. Nobody gets introduced to an investor before step two is done.
Find out where you are on your investor readiness
A conversation about your financial model, your pitch deck, your accounting, and the raise you are planning. You leave knowing how far you are from ready and what it would take to get there.
Get your ducks in a row with Malgorzata
An assessment of where you stand, a plan built with your team, then guided execution across the work streams that matter: business model, financial model, pitch deck, data room, budget, processes and controls.
For an early-stage company that means the basic documents done right. For a 50-to-100-person company it means the structure investors expect. Malgorzata guides and gets into the details. Your team does the work.
Get connected to investors in her network
Once she is confident you are ready, introductions to angels, venture funds, and private equity firms in her network, matched to the size and type of your raise. She does not introduce a company that is not ready, which is why her introductions land.
Who this is for
Raising $5M or more
Health tech, life science, medtech, and pharma companies planning a serious round, or already at around $10M in revenue.
Scientist-led teams
Founders who are excellent at the science and vague about the business model. Investors need to see where the money is made.
Outgrowing startup mode
Companies at 50 to 100 people that need processes, controls, and governance to scale, and to survive diligence.
Raising less than that? Ask anyway. If she likes the company, she makes exceptions.
The person you will actually be working with.
Answers to Margo
Her full name is Małgorzata, pronounced mal-go-ZHA-ta. Margo is fine, and she will not correct you.
Three languages, four countries
Native Polish and French, fluent English. She has run finance in Warsaw, Paris, London, and now Charlotte, with teams in Japan, India, and Australia along the way.
Four chairs at the table
External Big 4 auditor, head of internal audit, CFO, and investor. She has sat in every seat a diligence meeting has.
Cars before pills
Three years building internal controls across Nissan Europe before moving into private equity-owned pharma.
Teacher at heart
A PhD in management science, guest lectures on finance, and co-chair of the education committee at the Private Directors Association.
Writes checks too
A member of the Charlotte Angel Fund, so she sees early-stage deals from the investor side of the table, not just the founder side.
Find out where you are on your investor readiness.
The first step is a complimentary 30-minute call. Malgorzata will ask where your financial model, pitch deck, and accounting stand, and tell you honestly how far you are from ready.